Other · developed by JOHNSON & JOHNSON
JNJ-1761981 is an investigational agent administered intratumorally. It is studied in neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07525141 | Phase 1 | Neoplasms | Recruiting | JNJ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neoplasms
Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.
See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JNJ catalysts and pipeline →